Lethal congenital contracture syndrome 2
MONDO:0011868Lethal congenital contracture syndrome type 2 is a rare arthrogryposis syndrome characterized by multiple congenital contactures (typically extended elbows and flexed knees), micrognathia, anterior horn cell degeneration, skeletal muscle atrophy (mainly in the lower limbs), presence of a markedly distended urinary bladder and absence of hydrops, pterygia and bone fractures. Other craniofacial (e.g. cleft palate, facial palsy) and ocular (e.g. anisocoria, retinal detachment) anomalies may be additionally observed. The disease is usually neonatally lethal however, survival into adolescence has been reported.
Also known as: ERBB3 lethal congenital contracture syndrome, LCCS2, lethal congenital contractural syndrome 2, lethal congenital contracture syndrome 2, lethal congenital contracture syndrome caused by mutation in ERBB3, lethal congenital contracture syndrome type 2, multiple contracture syndrome, Israeli-Bedouin type, multiple contracture syndrome, Israeli Bedouin type
4 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New combo therapy aims to tackle tough lung cancer
Disease control Recruiting nowThis study tests two experimental drugs, BNT326 and BNT327, in people with advanced non-small cell lung cancer that has spread or come back. The trial has three parts to find the best dose and check safety, and will compare the combination to standard treatments like pembrolizuma…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New lung cancer vaccine trial launches for advanced patients
Disease control Recruiting nowThis early-stage trial is testing a new cancer vaccine called BNT116, alone or with other drugs, in people with advanced non-small cell lung cancer. The main goal is to find a safe dose and check for side effects. About 320 participants will be enrolled across several groups, inc…
Phase: PHASE1 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
BioNTech launches trial of BNT326 for advanced cancers
Disease control Recruiting nowThis study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC